MARKET

EVOK

EVOK

Evoke Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3000
-0.0007
-0.23%
After Hours: 0.2999 -0.0001 -0.03% 17:52 05/19 EDT
OPEN
0.3034
PREV CLOSE
0.3007
HIGH
0.3047
LOW
0.2848
VOLUME
667.65K
TURNOVER
0
52 WEEK HIGH
1.580
52 WEEK LOW
0.2261
MARKET CAP
12.04M
P/E (TTM)
-1.1274
1D
5D
1M
3M
1Y
5Y
Evoke Pharma Reports Findings For GIMOTI Survey
Patient Experience Survey Reported Positive Findings for GIMOTI® SOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused
Benzinga · 1d ago
Patient Experience Survey Reported Positive Findings for GIMOTI®
Research Study Among Patients Demonstrated Favorable Acceptance and Utilization of GIMOTISOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gast...
GlobeNewswire · 1d ago
Evoke Pharma to Present at H.C. Wainwright Global Investment Conference
SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today a...
GlobeNewswire · 2d ago
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Evoke Pharma: Q1 Earnings Insights
Evoke Pharma (NASDAQ:EVOK) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evoke Pharma missed estimated earnings by 75.0%, reporting an EPS of $-0.07 versus an esti...
Benzinga · 05/10 21:52
Evoke Pharma GAAP EPS of -$0.07 misses by $0.03, revenue of $0.42M misses by $0.12M
Evoke Pharma press release (NASDAQ:EVOK): Q1 GAAP EPS of -$0.07 misses by $0.03. Revenue of $0.42M (+366.7% Y/Y) misses by $0.12M. Existing cash and cash equivalents of $7.7M, as well
Seekingalpha · 05/10 20:37
Earnings Scheduled For May 10, 2022
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022
SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its first quarte...
GlobeNewswire · 05/03 12:30
More
No Data
Learn about the latest financial forecast of EVOK. Analyze the recent business situations of Evoke Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EVOK stock price target is 6.50 with a high estimate of 10.00 and a low estimate of 3.000.
High10.00
Average6.50
Low3.000
Current 0.3000
EPS
Actual
Estimate
-0.06-0.05-0.03-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 33
Institutional Holdings: 2.55M
% Owned: 7.97%
Shares Outstanding: 40.12M
TypeInstitutionsShares
Increased
5
48.51K
New
5
66.86K
Decreased
4
156.09K
Sold Out
3
2.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.15%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Cam Garner
President/Chief Executive Officer/Co-Founder/Director
David Gonyer
Executive Vice President/Treasurer/Secretary
Matthew D'Onofrio
Other
Marilyn Carlson
Director
Vickie Reed
Independent Director
Todd Brady
Independent Director
Malcolm Hill
Independent Director
Kenneth Widder
No Data
No Data
About EVOK
Evoke Pharma, Inc. (Evoke) is a specialty pharmaceutical company. Evoke operates in the development and commercialization of pharmaceutical products. Evoke is focused primarily on the development and commercialization of drugs to treat gastrointestinal( GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

Webull offers kinds of Evoke Pharma Inc stock information, including NASDAQ:EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.